Commodity Channel Index
|Bid||108.80 x 1400|
|Ask||108.83 x 1400|
|Day's Range||107.77 - 109.20|
|52 Week Range||72.67 - 125.52|
|Beta (5Y Monthly)||1.47|
|PE Ratio (TTM)||10.27|
|Earnings Date||Jul 22, 2020 - Jul 27, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||137.85|
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
Stocks to consider as biotech company Novavax gets $1.6 billion in federal aid for Covie-19 vaccine Continue reading...
Alexion Pharmaceuticals (NASDAQ: ALXN) is reaching into its coffers to settle charges leveled against it by the Securities and Exchange Commission. The SEC alleges that the company violated the Foreign Corrupt Practices Act, the federal anti-corruption law that bars U.S. corporations and citizens from bribing government officials abroad. Allegedly, two of Alexion's subsidiaries had paid foreign officials for favorable treatment for its blockbuster drug Soliris.
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Shares of Alexion Pharmaceuticals Inc. were up 0.1% in trading on Thursday after the Securities and Exchange Commission said the drugmaker would pay more than $21 million to resolve charges that it paid officials in Russian and Turkey to promise its immunosuppressive drug Soliris. The company allegedly paid government officials between 2010 and 2015 to encourage prescriptions of Soliris and secure "favorable regulatory treatment" for the drug. There are also allegations that subsidiaries in Brazil and Colombia failed to main accurate records. Alexion did not admit fault or deny the SEC's findings. Soliris is Alexion's top-selling drug, bringing in about $3.9 billion in sales in 2019. Alexion's stock has gained 3.9% year-to-date, while the S&P 500 is down 3.5%.
ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults and Children with Atypical Hemolytic Uremic Syndrome
Health care, one of the largest and most complex sectors, is comprised of a broad range of companies that sell medical products and services. The health care sector includes companies that sell drugs, medical devices, and insurance, as well as hospitals and health care providers. Health care stocks, as represented by the Health Care Select Sector SPDR ETF (XLV), have outperformed the broader market, providing investors with a total return of 6.8% compared to the S&P 500's total return of 5.5% over the past 12 months. The market performance numbers and the statistics in the tables in this story are as of June 24.
Alexion Announces Phase 3 Study of Weekly Subcutaneous ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint.
Alexion Charitable Foundation Announces First Rare Belonging® Grants Funding supports efforts by National Organization for Rare Disorders (NORD)
Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the Bank of America Virtual Napa Biotech Conference on Monday, June 22nd, 2020 at 2:00 p.m. ET.
What an absolutely wild time to be an investor. Since mid-February, Wall Street and investors have witnessed a peak decline in the benchmark S&P 500 of 34% -- a decline, mind you, that took less than five weeks -- as well as one heck of a rebound that sent the technology-heavy Nasdaq Composite to an all-time high above 10,000. With that being said, if you have, say, $2,000 in disposable cash (i.e., money that won't be needed for bills or an emergency fund) that you can used for investment purposes, then you should consider following in the footsteps of the smartest investors and buy these stocks hand over fist.
At the other end of the spectrum, though, some of the market's most compelling names remain priced below their typical valuations. To that end, here's a rundown of three great value stocks that aren't likely to stay this cheap for much longer.
Shares of Viela Bio Inc. were up 4.9% in premarket trading on Friday, the day after the company received approval from the Food and Drug Administration (FDA) to market Uplizna to treat neuromyelitis optica spectrum disorder. It is the second treatment for the rare neuroinflammatory disorder to receive FDA approval. The drug helps reduce the risk of attacks that can lead to paralysis and blindness. Viela said it plans to launch Uplizna this month; a company spokesperson declined to provided pricing information at this time but said the drug will be priced "favorably" and "significantly lower" than Alexion Pharmaceuticals Inc.'s Soliris. Stifel analysts predict roughly $500 million in sales of Uplizna in the U.S. per year. "From our review of the label, it looks largely in-line with base case expectations," they wrote in a June 12 note to investors. Viela's stock is up 89.5% year-to-date. The S&P 500 is down 7.1% since the start of the year.
Shares of Apellis Pharmaceuticals Inc. gained 5.1% in premarket trading on Friday after it shared details from a late-stage clinical trial evaluating its experimental drug pegcetacoplan against Alexion Pharmaceuticals Inc.'s Soliris as a treatment for paroxysmal nocturnal hemoglobinuria. The study found that pegcetacoplan was better than Soliris in improving hemoglobin levels in adults with the rare blood disease. Soliris brought in $3.9 billion in revenue in 2019. Apellis said it plans to submit a new drug application for pegcetacoplan to the Food and Drug Administration in the second half of the year. Its stock is down 0.5% year-to-date, while the S&P 500 has declined 7.1%.
Miller Value Partners recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Miller Value Partners Opportunity Equity Fund posted a return of -38.4% for the quarter (net of fees), underperforming its benchmark, the S&P 500 Index which returned -19.6% in the same quarter. You should check out Miller […]
The 2016-released report shows that value stocks averaged an annual gain of 17% between 1926 and 2015, compared to 12.6% for growth stocks. If you have $1,000 in spare cash that you won't need to pay bills or for emergencies, then consider the following value stocks, which are just begging to be bought.